United TherapeuticsFRA:UTH -2.65%82 EBITDA Margin % is 44.01% as of Mar. 2026, which is 15% below its 10-year median of 51.55. GuruFocus rates FRA:UTH with a GF Score™ of 82/100 and a GF Value™ of €337.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, United Therapeutics ranks better than 97.07% on this metric.
United Therapeutics (FRA:UTH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
United Therapeutics EBITDA Margin % Related Terms
United Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a EBITDA Margin % of 44.01% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on United Therapeutics and its competitors. This is 15% below median its historical median of 51.55. According to the industry distribution chart, United Therapeutics ranks #28 out of 955 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is United Therapeutics' EBITDA Margin % too high?
United Therapeutics' current EBITDA Margin % of 44.01% is 15% below median its 10-year median of 51.55. The Drug Manufacturers industry median EBITDA Margin % is 12.44. United Therapeutics' value of 44.01% is 253.8% above this industry median. Based on the distribution chart, United Therapeutics ranks #28 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' EBITDA Margin % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #28 out of 955 companies for EBITDA Margin %. This places United Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. United Therapeutics' value of 44.01% is 253.8% above this benchmark. While the company's 10-year median is 51.55 vs. the industry median of 12.44, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current EBITDA Margin % of 44.01% is 253.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current EBITDA Margin % is 44.01%, which is 15% below median its own 10-year median of 51.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €337.25, compared to a current price of €473.30 — trading 40.3% above its estimated fair value. The current EBITDA Margin % is 44.01%, which is 15% below median its 10-year median of 51.55 and 253.8% above the Drug Manufacturers industry median of 12.44. United Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current EBITDA Margin % is 44.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €473.30 is trading 40.3% above its estimated GF Value™ of €337.25.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
EBITDA Margin %: 44.01% (15% below median its 10-year median of 51.55)
GF Value™: €337.25 vs. price of €473.30 (40.3% above fair value)
Industry Position: 253.8% above the Drug Manufacturers median (#28 of 955)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
82GF Score
Get the complete analysis for FRA:UTH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
